Snow forces postponement of FDA oncologic drug advisory meeting
This article was originally published in Scrip
Executive Summary
The US FDA's oncologic drugs advisory committee has postponed its February 10th meeting, where it was to consider new drug applications from Cell Therapeutics for pixantrone dimaleate (Pixuvri) in patients with non-Hodgkin's lymphoma (NHL) and ChemGenex Pharmaceuticals for omacetaxine mepesuccinate (Omapro) for patients with chronic myeloid leukaemia (CML).